MedWatch

Swedish bank slashes Novo Nordisk price target ahead of 2022 outlook

Swedish bank Handelsbanken has reduced its share price target for Novo Nordisk by DKK 95 (USD 14.5) due to uncertainties about the pharmaceutical company's forecast for 2022, slated to be publicized on February 2.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Swedish bank Handelsbanken has lowered its share price target for Novo Nordisk from DKK 745 (USD 113.5) to DKK 650 (USD 99), while the bank's recommendation remains on "hold," Handelsbanken reports in an analysis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs